Recombinant human PTH 1-34 (Forteo): an anabolic drug for osteoporosis.
C Deal, J Gideon - Cleveland Clinic journal of medicine, 2003 - europepmc.org
C Deal, J Gideon
Cleveland Clinic journal of medicine, 2003•europepmc.orgForteo (teriparatide of rDNA origin), a genetically engineered fragment of parathyroid
hormone, is the first of a new class of drugs to treat osteoporosis. The drug's anabolic action
increases bone turnover, stimulating osteoblasts to a greater extent than osteoclasts, and
reducing both vertebral and nonvertebral fractures. However, a number of issues about its
use remain unanswered.
hormone, is the first of a new class of drugs to treat osteoporosis. The drug's anabolic action
increases bone turnover, stimulating osteoblasts to a greater extent than osteoclasts, and
reducing both vertebral and nonvertebral fractures. However, a number of issues about its
use remain unanswered.
Forteo (teriparatide of rDNA origin), a genetically engineered fragment of parathyroid hormone, is the first of a new class of drugs to treat osteoporosis. The drug's anabolic action increases bone turnover, stimulating osteoblasts to a greater extent than osteoclasts, and reducing both vertebral and nonvertebral fractures. However, a number of issues about its use remain unanswered.
europepmc.org